What Is the Best ETF to Buy This Year?
The stock market has gotten off to an extremely rough…
Sell
25
AARD Quote, Financials, Valuation and Earnings
Last price:
$8.69
Seasonality move
:
--
Day range:
$8.34 - $9.19
52-week range:
$6.79 - $19.58
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
149.3K
Avg. volume:
131.2K
1-year change:
--
Market cap:
$187M
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingAardvark Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $32.33, Aardvark Therapeutics has an estimated upside of 265.43% from its current price of $8.62.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $21.00 representing 100% downside risk from its current price of $8.62.
Fair Value
-
According to the consensus of 2 analysts, Aardvark Therapeutics has 265.43% upside to fair value with a price target of $32.33 per share.
AARD vs. S&P 500
-
Over the past 5 trading days, Aardvark Therapeutics has overperformed the S&P 500 by 0.16% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Aardvark Therapeutics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Aardvark Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Aardvark Therapeutics reported revenues of --.
Earnings Growth
-
Aardvark Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Aardvark Therapeutics reported earnings per share of --.
Enterprise value:
113.4M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -$18.1M | -$2.1M | -$9.5M | |
| EBITDA | -- | -- | -$18M | -$2.1M | -$9.5M | |
| Diluted EPS | -- | -- | -$0.93 | -$0.16 | -$0.41 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | $10.4M | $74.1M | |
| Total Assets | -- | -- | -- | $10.5M | $77.5M | |
| Current Liabilities | -- | -- | -- | $1.4M | $4.9M | |
| Total Liabilities | -- | -- | -- | $45.3M | $132.2M | |
| Total Equity | -- | -- | -- | -$34.8M | -$54.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -$4.7M | -$10.4M | |
| Cash From Investing | -- | -- | -- | -- | -$103K | |
| Cash From Financing | -- | -- | -- | -- | $83M | |
| Free Cash Flow | -- | -- | -- | -$4.7M | -$10.5M | |
AARD
Sector
Market Cap
$187M
--
Price % of 52-Week High
44.03%
--
Dividend Yield
0%
--
Shareholder Yield
--
--
1-Year Price Total Return
--
--
Beta (5-Year)
--
--
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$8.61
200-day SMA
Buy
Level
$0.00
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
-311K
20-day SMA
Sell
Level
$9.29
Relative Strength Index (RSI14)
Sell
Level
40.95
ADX Line
Buy
Level
28.2
Williams %R
Neutral
Level
-50.8065
50-day SMA
Buy
Level
$0.00
MACD (12, 26)
Buy
Level
0.10
25-day Aroon Oscillator
Sell
Level
-84
On Balance Volume
Neutral
Level
1.2M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
--
Momentum Score
Level (--)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Stock Forecast FAQ
In the current month, AARD has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AARD average analyst price target in the past 3 months is $32.33.
-
Where Will Aardvark Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Aardvark Therapeutics share price will rise to $32.33 per share over the next 12 months.
-
What Do Analysts Say About Aardvark Therapeutics?
Analysts are divided on their view about Aardvark Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Aardvark Therapeutics is a Sell and believe this share price will drop from its current level to $21.00.
-
What Is Aardvark Therapeutics's Price Target?
The price target for Aardvark Therapeutics over the next 1-year time period is forecast to be $32.33 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AARD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Aardvark Therapeutics is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AARD?
You can purchase shares of Aardvark Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Aardvark Therapeutics shares.
-
What Is The Aardvark Therapeutics Share Price Today?
Aardvark Therapeutics was last trading at $8.69 per share. This represents the most recent stock quote for Aardvark Therapeutics. Yesterday, Aardvark Therapeutics closed at $8.62 per share.
-
How To Buy Aardvark Therapeutics Stock Online?
In order to purchase Aardvark Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Bad News Priced Into Nike Stock Now?
Despite its dominance in the athletic shoe and apparel industry,…
Is LUV Stock a Buy, Sell or Hold?
Southwest Airlines (NYSE:LUV) is one of America’s major air transportation…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 33x
Sell
43
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
37
Is NVDA Stock a Buy?
Market Cap: $2.5T
P/E Ratio: 35x
Alerts
Sell
29
RH alert for Apr 4
RH [RH] is down 40.01% over the past day.
Sell
24
DPST alert for Apr 4
Direxion Daily Regional Banks Bull 3X Shares [DPST] is down 31.13% over the past day.
Buy
81
SOXS alert for Apr 4
Direxion Daily Semiconductor Bear 3X Shares [SOXS] is up 30.78% over the past day.
